• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌中p53和K-ras基因的突变对比分析

Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.

作者信息

Berrozpe G, Schaeffer J, Peinado M A, Real F X, Perucho M

机构信息

Department d'Immunologia, Universitat Autònoma de Barcelona, Spain.

出版信息

Int J Cancer. 1994 Jul 15;58(2):185-91. doi: 10.1002/ijc.2910580207.

DOI:10.1002/ijc.2910580207
PMID:8026879
Abstract

Mutations in codon 12 of K-ras occur in a high proportion of pancreatic cancer cases. Although there is evidence that p53 mutations also occur in this tumor, few studies have been reported to date and no comparison has been made of K-ras and p53 mutations in the same tissues. Single-strand conformation polymorphism and sequencing of the PCR products were used to determine mutations in p53 gene; to detect mutations in K-ras genes, the artificial restriction fragment length polymorphism (RFLP) approach was used. Eight out of 30 tissues from primary pancreas cancer and 3 of 4 samples from metastases showed p53 mutations. Fifteen out of 17 pancreatic cancer cell lines had p53 mutations. In 2 cases, the same p53 mutation was identified in the original tumor and in a tumor-derived cell line. The majority of p53 mutations were present in exons 5-9 of the gene. Mutations at codon 12 of the K-ras gene were identified in 23/32 pancreas cancer tissues and in 14/17 cell lines. There was no relationship between the types of mutation observed in the 2 genes. In conclusion, mutations in K-ras and p53 genes are common in pancreatic cancer. p53 mutations may occur more frequently in metastatic lesions than in primary tumors, although further work is necessary to investigate this point.

摘要

在胰腺癌病例中,K-ras基因第12密码子的突变发生率很高。虽然有证据表明p53基因在这种肿瘤中也会发生突变,但迄今为止报道的研究很少,并且尚未对同一组织中的K-ras和p53突变进行比较。采用单链构象多态性和PCR产物测序来确定p53基因的突变;为检测K-ras基因的突变,采用了人工限制性片段长度多态性(RFLP)方法。30例原发性胰腺癌组织中有8例以及4例转移灶样本中有3例显示出p53突变。17株胰腺癌细胞系中有15株存在p53突变。在2例病例中,在原发肿瘤和肿瘤衍生的细胞系中鉴定出相同的p53突变。大多数p53突变存在于该基因的第5至9外显子中。在23/32例胰腺癌组织和14/17株细胞系中鉴定出K-ras基因第12密码子的突变。在这两个基因中观察到的突变类型之间没有关联。总之,K-ras和p53基因的突变在胰腺癌中很常见。p53突变在转移灶中可能比在原发性肿瘤中更频繁地发生,不过还需要进一步研究来证实这一点。

相似文献

1
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.胰腺癌中p53和K-ras基因的突变对比分析
Int J Cancer. 1994 Jul 15;58(2):185-91. doi: 10.1002/ijc.2910580207.
2
Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.胰腺导管腺癌中的Ki-ras和p53突变
Pancreas. 1996 Jan;12(1):10-7. doi: 10.1097/00006676-199601000-00002.
3
Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation.胰液中p53肿瘤抑制基因的突变检测及其在胰腺癌患者诊断中的应用:与K-ras突变的比较
Clin Cancer Res. 1999 May;5(5):1147-53.
4
K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.人胰腺腺癌细胞系基因组DNA和转录本中的K-ras和p53改变
Jpn J Cancer Res. 1994 Oct;85(10):1005-14. doi: 10.1111/j.1349-7006.1994.tb02898.x.
5
Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.原发性和转移性胰腺导管病变的分子病理学:散发性和家族性病变中p53、mdm-2和p21/WAF-1基因的突变及表达分析
Cancer. 1997 Feb 15;79(4):700-16.
6
Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.人子宫内膜癌前病变和恶性病变中p53肿瘤抑制基因的改变及其与c-K-ras-2原癌基因激活的关系。
Cancer Res. 1993 Apr 15;53(8):1883-8.
7
Patterns of genetic alterations in pancreatic cancer: a pooled analysis.胰腺癌的基因改变模式:一项汇总分析。
Environ Mol Mutagen. 1999;33(2):111-22. doi: 10.1002/(sici)1098-2280(1999)33:2<111::aid-em3>3.0.co;2-f.
8
Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.胰腺腺癌中K-ras突变与p53畸变联合存在的患病率及临床意义
Int J Pancreatol. 1997 Apr;21(2):127-43. doi: 10.1007/BF02822384.
9
K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.仓鼠胰腺导管腺癌及细胞系中的K-ras和p53突变
Am J Pathol. 1996 Oct;149(4):1333-9.
10
p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.人胰腺导管腺癌中的p53、Ki-ras和DNA倍体
Lab Invest. 1996 Jan;74(1):279-89.

引用本文的文献

1
Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS.针对KRAS基因第12密码子突变的结构导向药物设计策略的演变
RSC Med Chem. 2025 May 26. doi: 10.1039/d5md00169b.
2
Rac1 GTPase Regulates the βTrCP-Mediated Proteolysis of YAP Independently of the LATS1/2 Kinases.Rac1 GTP酶独立于LATS1/2激酶调节βTrCP介导的YAP蛋白水解。
Cancers (Basel). 2024 Oct 25;16(21):3605. doi: 10.3390/cancers16213605.
3
Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.
利用多组学分析鉴定 TPI1 作为具有 TP53 突变依赖性的胰腺癌潜在治疗靶点。
Cancer Sci. 2024 Nov;115(11):3622-3635. doi: 10.1111/cas.16302. Epub 2024 Sep 11.
4
Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis.揭示相互作用:在胰腺胚胎发生背景下探索胰腺癌中的信号通路。
Front Cell Dev Biol. 2024 Aug 22;12:1461278. doi: 10.3389/fcell.2024.1461278. eCollection 2024.
5
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.TP53、CDKN2A、SMAD4和KRAS在胰腺癌中的意义
Curr Issues Mol Biol. 2024 Mar 23;46(4):2827-2844. doi: 10.3390/cimb46040177.
6
PR55α-controlled protein phosphatase 2A inhibits p16 expression and blocks cellular senescence induction by γ-irradiation.PR55α 调控的蛋白磷酸酶 2A 抑制 p16 的表达并阻断 γ 射线诱导的细胞衰老。
Aging (Albany NY). 2024 Mar 4;16(5):4116-4137. doi: 10.18632/aging.205619.
7
KRAS Inhibitor that Simultaneously Inhibits Nucleotide Exchange Activity and Effector Engagement.同时抑制核苷酸交换活性和效应物结合的KRAS抑制剂。
ACS Bio Med Chem Au. 2022 Sep 26;2(6):617-626. doi: 10.1021/acsbiomedchemau.2c00045. eCollection 2022 Dec 21.
8
Engineering of biomaterials for tumor modeling.用于肿瘤建模的生物材料工程
Mater Today Adv. 2020 Dec;8. doi: 10.1016/j.mtadv.2020.100117. Epub 2020 Nov 12.
9
Anthraquinones as Inhibitors of SOS RAS-GEF Activity.蒽醌类化合物作为 SOS RAS-GEF 活性的抑制剂。
Biomolecules. 2021 Jul 30;11(8):1128. doi: 10.3390/biom11081128.
10
BRCA2 Promotes Spontaneous Homologous Recombination In Vivo.BRCA2在体内促进自发同源重组。
Cancers (Basel). 2021 Jul 21;13(15):3663. doi: 10.3390/cancers13153663.